Cantor Fitzgerald Maintains Overweight on Catalyst Pharmaceuticals, Raises Price Target to $27
Portfolio Pulse from richadhand@benzinga.com
Cantor Fitzgerald analyst Charles Duncan maintains an Overweight rating on Catalyst Pharmaceuticals (NASDAQ:CPRX) and raises the price target from $25 to $27.
August 11, 2023 | 5:54 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cantor Fitzgerald has maintained an Overweight rating on Catalyst Pharmaceuticals and raised the price target from $25 to $27.
The news of Cantor Fitzgerald maintaining an Overweight rating and raising the price target for Catalyst Pharmaceuticals is likely to be seen as a positive signal by the market, potentially leading to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100